Clinical Trial Update: A 12-Week Study in Asthmatic Children Ages 6 to <12 Years, Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, Compared With Budesonide pMDI 80 μg [Phase 3]

View source ↗

Summary

A Phase 3 trial in children with asthma (ages 6 to <12) compared two Symbicort inhalers (80/2.25 μg and 80/4.5 μg) against budesonide inhaler (80 μg); results h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Budesonide pMDI 80 μg (budesonide)
• Symbicort pMDI 80/2.25 μg (budesonide/formoterol)
• Symbicort pMDI 80/4.5 μg (budesonide/formoterol)

Snippet

Sponsor: AstraZeneca | Conditions: Asthma | Phase 3 | Status: COMPLETED | Results posted: 2017-04-10